Diuril

Nephrotic Syndrome, Ascites, Edema + 23 more

Treatment

30 FDA approvals

20 Active Studies for Diuril

What is Diuril

Hydrochlorothiazide

The Generic name of this drug

Treatment Summary

Hydrochlorothiazide is a diuretic used to treat fluid retention and high blood pressure. It is the most commonly prescribed thiazide diuretic, but its use is declining in favor of other medications like angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Hydrochlorothiazide was approved by the FDA in 1959 and is available in combination with other medications.

Esidrix

is the brand name

Diuril Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Esidrix

Hydrochlorothiazide

1959

2181

Approved as Treatment by the FDA

Hydrochlorothiazide, also called Esidrix, is approved by the FDA for 30 uses including calcium channel blockers and inadequate response to other therapeutic measures .

calcium channel blockers

Used to treat calcium channel blockers in combination with Eprosartan

inadequate response to other therapeutic measures

Used to treat inadequate response to other therapeutic measures in combination with Spironolactone

Premenstrual tension with edema

Helps manage Premenstrual tension with edema

Left Ventricular Hypertrophy

Used to treat Left Ventricular Hypertrophy in combination with Losartan

Hypertension

Used to treat Antihypertensive Treatment in combination with Eprosartan

Hypertension

Used to treat blood pressure inadequately controlled with monotherapy in combination with Irbesartan

prophylaxis of preeclampsia

Helps manage prophylaxis of preeclampsia

Swollen feet or ankles

Used to treat Edema in combination with Triamterene

Hypertension, Essential Hypertension

Used to treat Hypertension, Essential Hypertension in combination with Spironolactone

Congestive Heart Failure

Used to treat Congestive Heart Failure (CHF) in combination with Spironolactone

Diuretics

Used to treat Hypokalemia caused by diuretics in combination with Amiloride

Hypertensive disease

Used to treat Hypertension, Essential Hypertension in combination with Spironolactone

Antepartum magnesium sulfate prophylaxis

Helps manage prophylaxis of preeclampsia

Hypertrophy, Left Ventricular

Used to treat Left Ventricular Hypertrophy in combination with Losartan

Stroke

Used to treat Cerebrovascular Accident in combination with Losartan

Edema

Used to treat Edema in combination with Triamterene

Cirrhosis of the Liver

Used to treat Cirrhosis of the Liver in combination with Spironolactone

Nephrotic Syndrome

Used to treat Nephrotic Syndrome in combination with Spironolactone

Hypertension

Used to treat inadequate control of blood pressure with monotherapy in combination with Aliskiren

Congestive Heart Failure (CHF)

Used to treat Congestive Heart Failure (CHF) in combination with Spironolactone

Hypokalemia

Used to treat hypokalemia with solo treatment in combination with Triamterene

Ascites

Used to treat Ascites in combination with Spironolactone

Therapeutic procedure

Used to treat inadequate response to treatment in combination with Spironolactone

Ascites

Used to treat Ascites in combination with Spironolactone

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Losartan

Sodium retention

Used to treat Sodium retention in combination with Spironolactone

Bedrest

Used to treat Bedrest in combination with Spironolactone

Cirrhosis

Used to treat Cirrhosis of the Liver in combination with Spironolactone

restriction of fluid and sodium

Used to treat restriction of fluid and sodium in combination with Spironolactone

Edema

Helps manage Premenstrual tension with edema

Effectiveness

How Diuril Affects Patients

Hydrochlorothiazide helps the body get rid of extra water and salt by preventing them from being reabsorbed in the kidneys. The amount of the drug taken can range from 25-100mg, depending on the individual. People with reduced kidney or liver function should be careful when taking this drug.

How Diuril works in the body

Hydrochlorothiazide works by blocking sodium from being reabsorbed by cells in the distal convoluted tubule, a part of the kidney. It is transported to these cells by special transporters, and then moved to the lumen of the tubule. Normally, sodium is reabsorbed into these cells and pumped into the surrounding area. This creates a concentration gradient that attracts water. By blocking sodium reabsorption, hydrochlorothiazide reduces the size of this gradient and therefore the reabsorption of water.

When to interrupt dosage

The suggested measure of Diuril is governed by the diagnosed circumstance, such as Antepartum magnesium sulfate prophylaxis, blood pressure inadequately managed with monotherapy and antihypertensives. The magnitude of dosage is contingent upon the technique of delivery (e.g. Tablet, coated - Oral or Oral) as found in the table beneath.

Condition

Dosage

Administration

Therapeutic procedure

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Nephrolithiasis

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Hypertension

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Hypertensive disease

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Hypertrophy, Left Ventricular

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Edema

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Sodium retention

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Antepartum magnesium sulfate prophylaxis

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Diabetes Insipidus

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Congestive Heart Failure

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Cirrhosis

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Hypertension

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Hypokalemia

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Hypertension

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Swollen feet or ankles

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Renal tubular acidosis

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

restriction of fluid and sodium

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

calcium channel blockers

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Diuretics

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

prophylaxis of calcium nephrolithiasis

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule - Oral, Capsule, Capsule, gelatin coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated

Warnings

Diuril Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Anuria

Do Not Combine

There are 20 known major drug interactions with Diuril.

Common Diuril Drug Interactions

Drug Name

Risk Level

Description

Amifostine

Major

Hydrochlorothiazide may increase the hypotensive activities of Amifostine.

Cyclopentamine

Major

The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cyclopentamine.

Dofetilide

Major

The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Dofetilide.

Fenofibrate

Major

The therapeutic efficacy of Fenofibrate can be decreased when used in combination with Hydrochlorothiazide.

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Hydroxyzine.

Diuril Toxicity & Overdose Risk

The lowest toxic dose of hydrochlorothiazide in mice and rats is greater than 10g/kg. If someone has overdosed on this drug, they may experience low levels of potassium, chloride, and sodium in their blood, and should be treated with fluids, electrolytes, and oxygen to restore their health. In cases of low blood pressure, vasopressors may also be administered.

Diuril Novel Uses: Which Conditions Have a Clinical Trial Featuring Diuril?

158 active clinical trials are currently assessing the potential of Diuril for managing Cirrhosis, Edema and Congestive Heart Failure.

Condition

Clinical Trials

Trial Phases

Cirrhosis

47 Actively Recruiting

Phase 1, Not Applicable, Phase 3, Phase 2, Phase 4

prophylaxis of calcium nephrolithiasis

0 Actively Recruiting

Antepartum magnesium sulfate prophylaxis

20 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2, Phase 4, Phase 1

Ascites

2 Actively Recruiting

Not Applicable, Phase 2

Sodium retention

0 Actively Recruiting

Swollen feet or ankles

3 Actively Recruiting

Phase 2, Not Applicable

Congestive Heart Failure

13 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Hypertensive disease

30 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

inadequate response to other therapeutic measures

0 Actively Recruiting

Hypertension

0 Actively Recruiting

Diuretics

0 Actively Recruiting

restriction of fluid and sodium

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Hypertrophy, Left Ventricular

0 Actively Recruiting

Nephrotic Syndrome

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

calcium channel blockers

0 Actively Recruiting

Hypokalemia

0 Actively Recruiting

Hypertension

0 Actively Recruiting

Hypertension

0 Actively Recruiting

Bedrest

0 Actively Recruiting

Diuril Reviews: What are patients saying about Diuril?

1

Patient Review

7/3/2011

Diuril for Prevention of Calcium-Containing Kidney Stones

Do not recommend. I experienced an increase in headaches and nausea after taking this for only a month, then suddenly developed severe leg and foot cramps that landed me in the ER with low sodium levels.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about diuril

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of diuretic is Diuril?

"Diuril is a prescription medication used to treat the symptoms of edema and hypertension. It may be used alone or in combination with other medications. Diuril works by increasing the amount of urine produced, which helps rid the body of excess water and salt."

Answered by AI

What is Diuril used for?

"This medication is used to lower high blood pressure in order to prevent strokes, heart attacks, and kidney problems. Chlorothiazide is a diuretic that helps remove excess salt and water from the body by increasing urine output."

Answered by AI

How long does it take Diuril to work?

"After taking chlorothiazide, you will start urinating more frequently within two hours."

Answered by AI

Is Diuril a hydrochlorothiazide?

"The drugs chlorothiazide and hydrochlorothiazide are diuretics that are used to treat nephrogenic diabetes insipidus, high blood pressure, abdominal fluid retention, heart failure, and elevated levels of calcium in the blood."

Answered by AI

Clinical Trials for Diuril

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Have you considered Diuril clinical trials?

We made a collection of clinical trials featuring Diuril, we think they might fit your search criteria.
Go to Trials
Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Mumford Professional Centre in Halifax, Canada.

Remote Monitoring for Cardiovascular Disease

18+
All Sexes
Halifax, Canada

The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync. The question guiding this study is: Do patient clinical outcomes differ between those who use the CardioWatch 287-2 during the HEARTS in Sync program as compared to those who participate without using the CardioWatch 287-2? The comparison will happen between two non-randomized groups of patients who are enrolled in the HEARTS in Sync virtual CR program. The wearable device (CardioWatch 287-2), worn on patient's wrists, will provide clinicians with physiological information to better mirror the clinical oversight provided to an in-person CR program. Participants who choose to use the device will be asked to wear it daily. The clinical team will review weekly summary reports to help guide participant progress through the 13-week program. The primary objectives of this study are to: 1. Characterize participants (e.g., demographic health history, patient feedback) between those who choose to use the CardioWatch 287-2 device and those who do not. 2. Compare clinical outcomes between users and non-users of the device within the HEARTS in Sync program, by: 1. Tracking patient enrollment, attendance in virtual education sessions, and program completion rates, 2. Evaluating change in patient bloodwork outcomes, 3. Measuring change is physical ability, 4. Analyzing changes in eating behaviours, and 5. Examining quality of life using validated tools. 3. Asses the feasibility of the CardioWatch 287-2 for the HEARTS in Sync virtual CR program by: 1. Assessing device adherence 2. Reviewing patient feedback survey, and 3. Determining if clinician team were able to access and interpret data collected throughout the program The secondary objective of this study is to compare clinical outcomes of device users during the HEARTS in Sync program with patients who completed the on-site CR program. This research aims to better understand how a medical-grade device may improve virtual CR programming to extend clinical care to the community. As a result, this could lead to a more personalized care and better results for patients.

Waitlist Available
Has No Placebo

Mumford Professional Centre

Nicholas B Giacomantonio, Medical Doctor

Corsano Health B.V.

Image of National Institutes of Health Clinical Center in Bethesda, United States.

Meal Macronutrients for Blood Fat Levels

18 - 120
All Sexes
Bethesda, MD

Background: Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn more about how eating meals with different levels of nutrients affects fats in the blood. Specifically, they want to study people with too much body fat, too little body fat, and a kidney problem called nephrotic syndrome. Objective: To learn more about how different types of foods affect fat levels in the blood. Eligibility: People aged 18 years or older with a health condition that affects how their body handles fats. Healthy volunteers are also needed. Design: Participants will have 2 overnight stays in the clinic within 6 months. At each visit, after staying overnight, they will eat a breakfast casserole. At 1 visit, breakfast will be a high-fat, low carbohydrate meal. At the other, it will be a high-carbohydrate, low-fat meal. Participants will have a tube inserted into a vein in their arm. They will have blood drawn via the tube 12 times in 8 hours: 2 times before they eat the breakfast and 10 times after. Participants will have other tests during their stays: * A resting metabolic test captures the air they exhale and measures how much energy they use at rest. * A dual energy X-ray absorptiometry (DXA) scan measures how much fat and muscle they have. * A Fibroscan is a special type of ultrasound of the liver. * A body surface scan uses lasers to measure the total area of the body. * A bioelectric impedance (BIS) exam measures how fast small electric currents move through their body. Participants may opt to have a third visit. At this visit, the breakfast will be high in protein.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Rebecca J Brown, M.D.

Have you considered Diuril clinical trials?

We made a collection of clinical trials featuring Diuril, we think they might fit your search criteria.
Go to Trials
Image of Maimonides Medical Center in Brooklyn, United States.

Minocycline for Stroke

18+
All Sexes
Brooklyn, NY

The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older. The main questions it aims to answer are: 1. Does Minocycline improve \*National Institutes of Health Stroke Scale\* (NIHSS) scores at hospital discharge and 90 days post-stroke? 2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -\*Modified Rankin Scale\* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care? Researchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality. Participants will: 1. Be randomly assigned by block to receive either: Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only 2. Undergo neurological assessments using NIHSS \*National Institutes of Health Stroke Scale\* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke 3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses NIHSS: \*National Institutes of Health Stroke Scale\*, which is stroke severity scale, mRS: \*Modified Rankin Scale\*, which is stroke disability scale

Phase 2 & 3
Recruiting

Maimonides Medical Center

Qingliang T. Wang, MD, PhD

Have you considered Diuril clinical trials?

We made a collection of clinical trials featuring Diuril, we think they might fit your search criteria.
Go to Trials